{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1382825896002602249.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Randy L. Webb"}],"foaf:familyName":[{"@value":"Webb"}],"foaf:givenName":[{"@value":"Randy L."}]}],"career":[{"institution":{"notation":[{"@value":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Médecine Expérimentale (A.C., G.N.), Collège de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands."}]}}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1362825896002602368","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1161/hypertensionaha.107.108845"},{"@type":"URI","@value":"https://www.ahajournals.org/doi/full/10.1161/HYPERTENSIONAHA.107.108845"}],"notation":[{"@value":"Effects of Aliskiren on Blood Pressure, Albuminuria, and (Pro)Renin Receptor Expression in Diabetic TG(mRen-2)27 Rats"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1161/hypertensionaha.107.108845_1UOD90y8BC5gXHpzGB0Z3vEK5up"}]}